newsfilter
← Latest News
GlobeNewswire·

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for